<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33161233</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>103097</StartPage><MedlinePgn>103097</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103097</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.103097</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30473-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">CXCL13 is a B and T lymphocyte chemokine that mediates neuroinflammation through its receptor CXCR5. This chemokine is highly expressed by motoneurons (MNs) in Amyotrophic Lateral Sclerosis (ALS) SOD1G93A (mSOD1) mice during the disease, particularly in fast-progressing mice. Accordingly, in this study, we investigated the role of this chemokine in ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used in vitro and in vivo experimental paradigms derived from ALS mice and patients to investigate the expression level and distribution of CXCL13/CXCR5 axis and its role in MN death and disease progression. Moreover, we compared the levels of CXCL13 in the CSF and serum of ALS patients and controls.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">CXCL13 and CXCR5 are overexpressed in the spinal MNs and peripheral axons in mSOD1 mice. CXCL13 inhibition in the CNS of ALS mice resulted in the exacerbation of motor impairment (n&#xa0;=&#xa0;4/group;Mean_Diff.=27.81) and decrease survival (n&#xa0;=&#xa0;14_Treated:19.2&#xa0;&#xb1;&#xa0;1.05wks, n&#xa0;=&#xa0;17_Controls:20.2&#xa0;&#xb1;&#xa0;0.6wks; 95% CI: 0.4687-1.929). This was corroborated by evidence from primary spinal cultures where the inhibition or activation of CXCL13 exacerbated or prevented the MN loss. Besides, we found that CXCL13/CXCR5 axis is overexpressed in the spinal cord MNs of ALS patients, and CXCL13 levels in the CSF discriminate ALS (n&#xa0;=&#xa0;30) from Multiple Sclerosis (n&#xa0;=&#xa0;16) patients with a sensitivity of 97.56%.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We hypothesise that MNs activate CXCL13 signalling to attenuate CNS inflammation and prevent the neuromuscular denervation. The low levels of CXCL13 in the CSF of ALS patients might reflect the MN dysfunction, suggesting this chemokine as a potential clinical adjunct to discriminate ALS from other neurological diseases.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Vaccinex, Inc.; Regione Lombardia (TRANS-ALS).</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trolese</LastName><ForeName>Maria Chiara</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Biology of Neurodegenerative Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terao</LastName><ForeName>Mineko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Paola</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Biology of Neurodegenerative Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrizio</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sironi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosaki</LastName><ForeName>Mami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche IRCCS, Via Mario Negri 2, Milan 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcuzzo</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojsi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", P.zza Miraglia 2, Naples 80138, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Academic Medic\\\al Centre, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy. Electronic address: caterina.bendotti@marionegri.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy. Electronic address: giovanni.nardo@marionegri.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110663">CXCL13 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C095085">CXCR5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054382">Chemokine CXCL13</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054380">Receptors, CXCR5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054382" MajorTopicYN="N">Chemokine CXCL13</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054380" MajorTopicYN="N">Receptors, CXCR5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Chemokines</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Dr. Bendotti reports grants from Vaccinex Inc.; Dr. Nardo has nothing to disclose. Dr. Trolese has nothing to disclose. Dr Mariani has nothing to disclose. Dr. Terao has nothing to disclose. Dr. de Paola has nothing to disclose. Dr. Fabbrizio has nothing to disclose. Dr. Sironi has nothing to disclose. Dr. Kurosaki has nothing to disclose. Dr. Bonanno has nothing to disclose. Dr. Marcuzzo has nothing to disclose. Dr. Bernasconi has nothing to disclose. Dr. Trojsi has nothing to disclose. Dr. Aronica has nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>8</Day><Hour>20</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33161233</ArticleId><ArticleId IdType="pmc">PMC7670099</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.103097</ArticleId><ArticleId IdType="pii">S2352-3964(20)30473-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W. Amyotrophic lateral sclerosis. Nat Rev Dis Prim [Internet] 2017 Dec 5;3(1):17071. http://www.nature.com/articles/nrdp201771 Available from:</Citation></Reference><Reference><Citation>Hardiman O., van den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol [Internet] 2011 Nov 11;7(11):639&#x2013;649. http://www.nature.com/articles/nrneurol.2011.153 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Chi&#xf2; A., Couratier P., Esteban J., Hardiman O., Logroscino G. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Later Scler [Internet] 2011 Jan 11;12(1):1&#x2013;10. http://www.tandfonline.com/doi/full/10.3109/17482968.2010.502940 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.502940</ArticleId><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Bowser R., Bruijn L., Dupuis L., Ludolph A., McGrath M. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Later Scler Front Degener [Internet] 2013 May 16;14(sup1):19&#x2013;32. http://www.tandfonline.com/doi/full/10.3109/21678421.2013.778554 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778554</ArticleId><ArticleId IdType="pmc">PMC4284067</ArticleId><ArticleId IdType="pubmed">23678877</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron [Internet] 2006 Oct 5;52(1):39&#x2013;59. http://www.ncbi.nlm.nih.gov/pubmed/17015226 [cited 2015 Sep 22]. Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci [Internet] 2008 Mar 3;11(3):251&#x2013;253. http://www.nature.com/articles/nn2047 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol [Internet] 2018 Oct;31(5):635&#x2013;639. http://journals.lww.com/00019052-201810000-00018 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A [Internet] 2008 Oct 7;105(40):15558&#x2013;15563. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2547419&amp;tool=pmcentrez&amp;rendertype=abstract [cited 2015 Dec 12]. Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S a, Vartanian T.K. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A [Internet] 2008 Nov 18;105(46):17913&#x2013;17918. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2581614&amp;tool=pmcentrez&amp;rendertype=abstract Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron [Internet] 2009 Oct 15;64(1):93&#x2013;109. http://www.ncbi.nlm.nih.gov/pubmed/19840552 [cited 2013 Mar 14]Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">19840552</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Bendotti C. Major histocompatibility complex I expression by motor neurons and its implication in amyotrophic lateral sclerosis. Front Neurol [Internet] 2016 Jun 13;7(JUN) http://journal.frontiersin.org/Article/10.3389/fneur.2016.00089/abstract Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00089/abstract</ArticleId><ArticleId IdType="pmc">PMC4904147</ArticleId><ArticleId IdType="pubmed">27379008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon M.J., Shin H.Y., Cui Y., Kim H., Thi A.H.L., Choi J.Y. CCL2 mediates neuron-macrophage interactions to drive proregenerative macrophage activation following preconditioning injury. J Neurosci [Internet] 2015 Dec 2;35(48):15934&#x2013;15947. http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1924-15.2015 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1924-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605453</ArticleId><ArticleId IdType="pubmed">26631474</ArticleId></ArticleIdList></Reference><Reference><Citation>Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med [Internet] 2006 Feb 9;354(6):610&#x2013;621. http://www.nejm.org/doi/abs/10.1056/NEJMra052723 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra052723</ArticleId><ArticleId IdType="pubmed">16467548</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haas A.H., van Weering H.R.J., de Jong E.K., Boddeke H.W.G.M., Biber K.P.H. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol [Internet] 2007 Oct 10;36(2):137&#x2013;151. http://link.springer.com/10.1007/s12035-007-0036-8 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-007-0036-8</ArticleId><ArticleId IdType="pmc">PMC2039784</ArticleId><ArticleId IdType="pubmed">17952658</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarin-Vuaillat C., Ransohoff R.M. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics [Internet] 2007 Oct;4(4):590&#x2013;601. http://link.springer.com/10.1016/j.nurt.2007.07.004 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2007.07.004</ArticleId><ArticleId IdType="pmc">PMC7479679</ArticleId><ArticleId IdType="pubmed">17920540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Lindberg R.L.P., Regeniter A., Mehling M., Steck A.J., Kappos L. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol [Internet] 2009 Jun;16(6):771&#x2013;774. http://doi.wiley.com/10.1111/j.1468-1331.2009.02560.x Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F., Komine O., Yamanaka K. Neuroinflammation in motor neuron disease. Clin Exp Neuroimmunol [Internet] 2016 May;7(2):126&#x2013;138. http://doi.wiley.com/10.1111/cen3.12309 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen3.12309</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira G.P., Alves C.J., Chadi G. Early gene expression changes in spinal cord from SOD1G93A amyotrophic lateral sclerosis animal model. Front Cell Neurosci [Internet] 2013;7 http://journal.frontiersin.org/article/10.3389/fncel.2013.00216/abstract Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00216/abstract</ArticleId><ArticleId IdType="pmc">PMC3831149</ArticleId><ArticleId IdType="pubmed">24302897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Liu Y., Liu X., Li S., Cheng C., Chen S. Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model. Transl Neurodegener [Internet] 2018 Dec 21;7(1):35. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-018-0138-4 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-018-0138-4</ArticleId><ArticleId IdType="pmc">PMC6309063</ArticleId><ArticleId IdType="pubmed">30607245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., F&#xf6;rster R., Sedgwick J.D. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature [Internet] 2000 Jul;406(6793):309&#x2013;314. http://www.nature.com/articles/35018581 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">10917533</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster R., Mattis A.E., Kremmer E., Wolf E., Brem G., Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell [Internet] 1996 Dec;87(6):1037&#x2013;1047. https://linkinghub.elsevier.com/retrieve/pii/S0092867400817985 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">8978608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagaeva L.V, Rao P., Powers J.M., Segal B.M. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol [Internet] 2006 Jun 15;176(12):7676&#x2013;7685. http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.176.12.7676 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.12.7676</ArticleId><ArticleId IdType="pubmed">16751415</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R., Columba-Cabezas S., Serafini B., Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol [Internet] 2004 Mar;148(1&#x2013;2):11&#x2013;23. https://linkinghub.elsevier.com/retrieve/pii/S0165572803004983 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">14975582</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J.R., Braziel R.M., Paoletti S., Lipp M., Uguccioni M., Rosenbaum J.T. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood [Internet] 2003 Feb 1;101(3):815&#x2013;821. https://ashpublications.org/blood/article/101/3/815/88835/Expression-of-Bcellattracting-chemokine-1-CXCL13 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">12393412</ArticleId></ArticleIdList></Reference><Reference><Citation>Irani D.N. Regulated production of CXCL13 within the central nervous system. J Clin Cell Immunol [Internet] 2016;7(5) https://www.omicsonline.org/open-access/regulated-production-of-cxcl13-within-the-central-nervous-system-2155-9899-1000460.php?aid=80680 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461933</ArticleId><ArticleId IdType="pubmed">28603659</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M., Theil D., Cepok S., Hemmer B., Kivis&#xe4;kk P., Ransohoff R.M. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain [Internet] 2006 Jan 1;129(1):200&#x2013;211. http://academic.oup.com/brain/article/129/1/200/311844/Chemokines-in-multiple-sclerosis-CXCL12-and-CXCL13 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">16280350</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology [Internet] 2009 Dec 8;73(23):2003&#x2013;2010. http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e3181c5b457 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c5b457</ArticleId><ArticleId IdType="pubmed">19996075</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L., Korfel A., Pfeiffer S., Kiewe P., Volk H.-.D., Cakiroglu H. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res [Internet] 2009 Oct 1;15(19):5968&#x2013;5973. http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-09-0108 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-09-0108</ArticleId><ArticleId IdType="pubmed">19773382</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang B.-.C., Cao D.-.L, Zhang X., Zhang Z.-.J., He L.-.N, Li C.-.H. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest [Internet] 2016 Jan 11;126(2):745&#x2013;761. https://www.jci.org/articles/view/81950 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731172</ArticleId><ArticleId IdType="pubmed">26752644</ArticleId></ArticleIdList></Reference><Reference><Citation>Esen N., Rainey-Barger E.K., Huber A.K., Blakely P.K., Irani D.N. Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. Glia [Internet] 2014 Sep;62(9):1452&#x2013;1462. http://doi.wiley.com/10.1002/glia.22692 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22692</ArticleId><ArticleId IdType="pmc">PMC4143141</ArticleId><ArticleId IdType="pubmed">24829092</ArticleId></ArticleIdList></Reference><Reference><Citation>Monson N.L., Ortega S.B., Ireland S.J., Meeuwissen A.J.M., Chen D., Plautz E.J. Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke. J Neuroinflamm [Internet] 2014;11(1):22. http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-11-22 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-22</ArticleId><ArticleId IdType="pmc">PMC3926678</ArticleId><ArticleId IdType="pubmed">24485041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Iennaco R., Fusi N., Heath P.R., Marino M., Trolese M.C. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain [Internet] 2013 Nov;136(11):3305&#x2013;3332. https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awt250 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt250</ArticleId><ArticleId IdType="pubmed">24065725</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. El escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci [Internet] 1994 Jul;124:96&#x2013;107. https://linkinghub.elsevier.com/retrieve/pii/0022510X94901910 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimatcheva E., Pandina T., Reilly C., Torno S., Bussler H., Scrivens M. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol [Internet] 2015;16(1):6. http://www.biomedcentral.com/1471-2172/16/6 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329654</ArticleId><ArticleId IdType="pubmed">25879435</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Verderio M., Mariani A., de Paola M., Riva N. Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener [Internet] 2018 Dec 9;13(1):42. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-018-0271-7 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0271-7</ArticleId><ArticleId IdType="pmc">PMC6085701</ArticleId><ArticleId IdType="pubmed">30092791</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola M., Mariani A., Bigini P., Peviani M., Ferrara G., Molteni M. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med [Internet] 2012 Jun 1;18(6):971&#x2013;981. https://molmed.biomedcentral.com/articles/10.2119/molmed.2012.00020 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2012.00020</ArticleId><ArticleId IdType="pmc">PMC3459480</ArticleId><ArticleId IdType="pubmed">22562723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.-.P. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Later Scler [Internet] 2010 Jan 26;11(1&#x2013;2):38&#x2013;45. http://www.tandfonline.com/doi/full/10.3109/17482960903545334 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilkenny C., Browne W.J., Cuthill I.C., Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol [Internet] 2010 Jun 29;8(6) https://dx.plos.org/10.1371/journal.pbio.1000412 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000412</ArticleId><ArticleId IdType="pmc">PMC2893951</ArticleId><ArticleId IdType="pubmed">20613859</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Liu Y., Wang L., Li W. Age-related macular degeneration phenotypes are associated with increased tumor necrosis-alpha and subretinal immune cells in aged Cxcr5 knockout mice. Boulton ME, editor. PLoS One [Internet] 2017 Mar 10;12(3) https://dx.plos.org/10.1371/journal.pone.0173716 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0173716</ArticleId><ArticleId IdType="pmc">PMC5345864</ArticleId><ArticleId IdType="pubmed">28282423</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R., Mosley R.L., Reynolds A.D., Dhar A., Jackson-Lewis V., Gordon P.H. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. McCabe BD, editor. PLoS One [Internet] 2008 Jul 23;3(7):e2740. https://dx.plos.org/10.1371/journal.pone.0002740 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002740</ArticleId><ArticleId IdType="pmc">PMC2481277</ArticleId><ArticleId IdType="pubmed">18648532</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi Y., Kato M., Ozeki K., Ishigai M. Pharmacokinetics of an intracerebroventricularly administered antibody in rats. MAbs [Internet] 2017 Oct 3;9(7):1210&#x2013;1215. https://www.tandfonline.com/doi/full/10.1080/19420862.2017.1345834 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2017.1345834</ArticleId><ArticleId IdType="pmc">PMC5627584</ArticleId><ArticleId IdType="pubmed">28682148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M., Adah D., Tariq M., Lu Y., Zhang J., Liu J. CXCL13/CXCR5 signaling axis in cancer. Life Sci [Internet] 2019 Jun;227:175&#x2013;186. https://linkinghub.elsevier.com/retrieve/pii/S0024320519303157 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">31026453</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam [Internet] 2012;2012:1&#x2013;10. http://www.hindawi.com/journals/iji/2012/819467/ Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249891</ArticleId><ArticleId IdType="pubmed">22229105</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol [Internet] 2013 Jul;74(1):20&#x2013;38. http://doi.wiley.com/10.1002/ana.23937 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M., Papa S., Crippa V., Nardo G., Peviani M., Cheroni C. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol Aging [Internet] 2015 Jan;36(1):492&#x2013;504. http://www.ncbi.nlm.nih.gov/pubmed/25085783 [cited 2015 Dec 12]Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">25085783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Tortarolo M., Vallarola A., Freschi M., Pasetto L. New insights on the mechanisms of disease course variability in ALS from mutant SOD1 mouse models. Brain Pathol [Internet] 2016 Mar;26(2):237&#x2013;247. http://doi.wiley.com/10.1111/bpa.12351 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12351</ArticleId><ArticleId IdType="pubmed">26780365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh G., Borda J.T., Gill A., Ribka E.P., Morici L.A., Mottram P. Possible role of glial cells in the onset and progression of Lyme neuroborreliosis. J Neuroinflamm [Internet] 2009;6(1):23. http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-6-23 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-6-23</ArticleId><ArticleId IdType="pmc">PMC2748066</ArticleId><ArticleId IdType="pubmed">19706181</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan K., Dail D., Li L., Cadavid D., Amrute S., Fitzgerald-Bocarsly P. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol [Internet] 2005 Jun;57(6):813&#x2013;823. http://doi.wiley.com/10.1002/ana.20486 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20486</ArticleId><ArticleId IdType="pubmed">15929033</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M., Tortarolo M., Battaglia E., Piva R., Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. Mol Neurobiol [Internet] 2014 Feb 20;49(1):136&#x2013;148. http://link.springer.com/10.1007/s12035-013-8507-6 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8507-6</ArticleId><ArticleId IdType="pubmed">23873136</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallarola A., Sironi F., Tortarolo M., Gatto N., De Gioia R., Pasetto L. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J Neuroinflamm [Internet] 2018 Dec 1;15(1):65. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1101-0 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1101-0</ArticleId><ArticleId IdType="pmc">PMC5833072</ArticleId><ArticleId IdType="pubmed">29495962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowarik M.C., Cepok S., Sellner J., Grummel V., Weber M.S., Korn T. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflamm [Internet] 2012 Dec 16;9(1):624. http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-93 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-93</ArticleId><ArticleId IdType="pmc">PMC3418196</ArticleId><ArticleId IdType="pubmed">22591862</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht T.A., Plate A., Adam M., Wick M., Kastenbauer S., Schmidt C. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflamm [Internet] 2009;6(1):42. http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-6-42 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-6-42</ArticleId><ArticleId IdType="pmc">PMC2811704</ArticleId><ArticleId IdType="pubmed">20042073</ArticleId></ArticleIdList></Reference><Reference><Citation>Naor S., Keren Z., Bronshtein T., Goren E., Machluf M., Melamed D. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol [Internet] 2009 Aug 12;256(8):1228&#x2013;1235. http://link.springer.com/10.1007/s00415-009-5097-3 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5097-3</ArticleId><ArticleId IdType="pubmed">19280101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M., Rombos A., Nikolaou C., Zoga M., Zouvelou V., Dimitrakopoulos A. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand [Internet] 2010 Dec;122(6):425&#x2013;429. http://doi.wiley.com/10.1111/j.1600-0404.2010.01333.x Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2010.01333.x</ArticleId><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M., Chattopadhay M., La Cava A., Tse E., Liu G., Lourenco E. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation [Internet] 2010;7(1):76. http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-7-76 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger L.M., Shatz C.J. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci [Internet] 2004 Jul;5(7):521&#x2013;531. http://www.ncbi.nlm.nih.gov/pubmed/15208694 [cited 2013 Mar 12]. Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">15208694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Vargas M.R., Cassina P., Barbeito A.G., Beckman J.S., Barbeito L. Complexity of astrocyte-motor neuron interactions in amyotrophic lateral sclerosis. Neurodegen Dis [Internet] 2005;2(3&#x2013;4):139&#x2013;146. https://www.karger.com/Article/FullText/89619 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">16909019</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Miranda C.J., Braun L., Meyer K., Frakes A.E., Ferraiuolo L. Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat Med [Internet] 2016 Apr 29;22(4):397&#x2013;403. http://www.nature.com/articles/nm.4052 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., de Vito G., Cecchi R., Riva N., Dina G. Immune response in peripheral axons delays disease progression in SOD1G93A mice. J Neuroinflamm [Internet] 2016 Dec 7;13(1):261. http://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0732-2 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0732-2</ArticleId><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen C.D.C., Ansel K.M., Low C., Lesley R., Tamamura H., Fujii N. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol [Internet] 2004 Sep 1;5(9):943&#x2013;952. http://www.nature.com/articles/ni1100 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">15300245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarini F., Tham T.N., Casanova P., Arenzana-Seisdedos F., Dubois-Dalcq M. Role of the&#xa0;?-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia [Internet] 2003 Apr 15;42(2):139&#x2013;148. http://doi.wiley.com/10.1002/glia.10139 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10139</ArticleId><ArticleId IdType="pubmed">12655598</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.S., Rubin J.B. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol [Internet] 2004 Jun;25(6):306&#x2013;314. https://linkinghub.elsevier.com/retrieve/pii/S1471490604001188 Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">15145320</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumm R.K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci [Internet] 2002 Jul 15;22(14):5865&#x2013;5878. http://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.22-14-05865.2002 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-14-05865.2002</ArticleId><ArticleId IdType="pmc">PMC6757949</ArticleId><ArticleId IdType="pubmed">12122049</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro S., Lessi F., Duregotti E., Aretini P., La Ferla M., Franceschi S. &lt;scp&gt;CXCL&lt;/scp&gt;12&#x3b1;/ &lt;scp&gt;SDF&lt;/scp&gt;&#x2010;1 from perisynaptic Schwann cells promotes regeneration of injured motor axon terminals. EMBO Mol Med [Internet] 2017 Aug 30;9(8):1000&#x2013;1010. https://onlinelibrary.wiley.com/doi/abs/10.15252/emmm.201607257 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607257</ArticleId><ArticleId IdType="pmc">PMC5538331</ArticleId><ArticleId IdType="pubmed">28559442</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury Y., Collongues N., De S&#xe8;ze J., Gulsari V., Patte-Mensah C., Marcou G. Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. Analyst [Internet] 2019;144(15):4647&#x2013;4652. http://xlink.rsc.org/?DOI=C9AN00754G Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">31257384</ArticleId></ArticleIdList></Reference><Reference><Citation>Leypoldt F., H&#xf6;ftberger R., Titulaer M.J., Armangue T., Gresa-Arribas N., Jahn H. Investigations on CXCL13 in Anti - N -methyl- D - aspartate receptor encephalitis. JAMA Neurol [Internet] 2015 Feb 1;72(2):180. http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2014.2956 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836910</ArticleId><ArticleId IdType="pubmed">25436993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.H., Jang S.Y., Shin Y.K., Jo Y.R., Yoon B.-.A., Nam S.H. Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy. Sci Rep [Internet] 2019 Dec 11;9(1):16535. http://www.nature.com/articles/s41598-019-52643-2 Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6848485</ArticleId><ArticleId IdType="pubmed">31712675</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez E., Piccio L., Mikesell R.J., Klawiter E.C., Parks B.J., Naismith R.T. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler J [Internet] 2013 Aug 15;19(9):1204&#x2013;1208. http://journals.sagepub.com/doi/10.1177/1352458512473362 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512473362</ArticleId><ArticleId IdType="pmc">PMC3959125</ArticleId><ArticleId IdType="pubmed">23322500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen M.S., Nilsson A.C., Forsberg J., Milthers J., Wirenfeldt M., Bonde C. Use of cerebrospinal fluid biomarkers in diagnosis and monitoring of rheumatoid meningitis. Front Neurol [Internet] 2019 Jun 26;10 https://www.frontiersin.org/article/10.3389/fneur.2019.00666/full Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00666/full</ArticleId><ArticleId IdType="pmc">PMC6606769</ArticleId><ArticleId IdType="pubmed">31293505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>